Read by QxMD icon Read

aripiprazole hyperprolactinemia

Feng-Rong An, Rui Yang, Zhi-Min Wang, Gabor S Ungvari, Chee H Ng, Helen F K Chiu, Ping-Ping Wu, Xin Jin, Lu Li, Grace K I Lok, Yu-Tao Xiang
PURPOSE: To examine the frequency of hyperprolactinemia and the socio-demographic, clinical, and quality of life (QOL) correlates. The frequency of prolactin-related side effects and associated subjective experiences were also examined. METHODS: A cohort of 1364 psychiatric inpatients were consecutively recruited and evaluated. Basic socio-demographic and clinical data were collected. Psychopathology, prolactin-related side effects were measured using standardized instruments...
August 24, 2016: Comprehensive Psychiatry
Hui Woo Yoon, Jung Suk Lee, Sang Jin Park, Seon-Koo Lee, Won-Jung Choi, Tae Yong Kim, Chang Hyung Hong, Jeong-Ho Seok, Il-Ho Park, Sang Joon Son, Daeyoung Roh, Bo-Ra Kim, Byung Ook Lee
OBJECTIVES: Hyperprolactinemia is an important but often overlooked adverse effect of antipsychotics. Several studies have shown that switching to or adding aripiprazole normalizes antipsychotic-induced hyperprolactinemia. However, no study has directly compared the effectiveness and safety of the 2 strategies. METHODS: A total of 52 patients with antipsychotic-induced hyperprolactinemia were recruited. Aripiprazole was administered to patients with mild hyperprolactinemia (serum prolactin level < 50 ng/mL)...
July 19, 2016: Clinical Neuropharmacology
Sam Padamadan Joseph
Hyperprolactinemia is a common adverse effect of antipsychotic medication. Switching over to aripiprazole or adjunctive aripiprazole has been advocated for optimal management of antipsychotic-induced hyperprolactinemia. Adjunctive treatment with aripiprazole has been shown to normalize prolactin levels without affecting already achieved improvements in psychotic symptoms. However, here, we present the case of a 36 year old female with delusional disorder who developed symptomatic hyperprolactinemia while on aripiprazole treatment...
May 2016: Indian Journal of Psychological Medicine
Rintaro Sogawa, Yuki Shimomura, Chikako Minami, Joji Maruo, Yutaka Kunitake, Yoshito Mizoguchi, Toshiro Kawashima, Akira Monji, Hideo Hara
BACKGROUND: The increase in prolactin (PRL) levels is a common adverse effect that occurs when using conventional and atypical antipsychotic drugs. Aripiprazole (ARI) is beneficial for antipsychotic-associated hyperprolactinemia but has been reported to decrease PRL secretion. Therefore, we investigated blood levels of PRL in patients who had taken ARI alone or in combination with other antipsychotics. METHODS: Retrospective information was obtained from 25 psychiatric patients who were prescribed ARI, and the blood levels of PRL were measured...
August 2016: Journal of Clinical Psychopharmacology
Rebecca L Curran, Ismail A Badran, Virginia Peppers, Ernest V Pedapati, Christoph U Correll, Melissa P DelBello
No abstract text is available yet for this article.
June 2016: Journal of Child and Adolescent Psychopharmacology
Young-Min Park, Seung-Hwan Lee, Bun-Hee Lee, Kyu Young Lee, Kye-Seong Lee, Seung-Gul Kang, Hwa-Young Lee, Won Kim
The aims of this study were to clarify whether atypical antipsychotics can elevate serum levels of both macroprolactin and prolactin, and whether the macroprolactin levels differ according to the type of atypical antipsychotic being taken. In total, 245 subjects were enrolled consecutively in 6 hospitals. Serum prolactin and macroprolactin levels were measured at a single time point during maintenance antipsychotic monotherapy. The mean total serum prolactin levels including macroprolactin were 11.91, 20.73, 16...
May 30, 2016: Psychiatry Research
S S Potanin, D S Burminsky, M A Morozova, A I Platova, N V Baymeeva, I I Miroshnichenko
OBJECTIVE: To study a relationship between plasma levels of antipsychotics (AP) and severity of side-effects (SE) during the treatment of inpatients with exacerbation of schizophrenia. MATERIAL AND METHODS: The study included 39 patients treated with risperidone, haloperidol, zuclopenthixol, clozapine, aripiprazole or olanzapine as monotherapy or in combination of two AP. Blood sampling to measure the AP plasma level was performed twice (at 7-10 and 26-30 day from start of treatment), the levels of prolactin and glucose were determined once (at 26-30 day from start of treatment)...
2015: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
D Mété, C Dafreville, V Paitel, P Wind
INTRODUCTION: Aripiprazole, an atypical or second-generation antipsychotic, is usually well tolerated. It is an approved treatment for schizophrenia and mania in bipolar disorder type 1. Unlike the other antipsychotics, it has high affinity agonist properties for dopamine D2 and D3 receptors. It has also 5-HT1A partial agonist and 5-HT2A antagonist properties. Aripiprazole is a first or second line treatment frequently used because it has reduced side effects such as weight gain, sleepiness, dyslipidemia, insulin resistance, hyperprolactinemia and extrapyramidal symptoms...
June 2016: L'Encéphale
Ying Qiao, Fuzhong Yang, Chunbo Li, Qian Guo, Hui Wen, Suoyu Zhu, Qiong Ouyang, Weidi Shen, Jianhua Sheng
This study investigated the effects of a low-dose aripiprazole adjunctive treatment for risperidone- or paliperidone-induced hyperprolactinemia in Han Chinese women with schizophrenia. After 4 weeks of risperidone or paliperidone treatment, 60 out of 66 patients improved significantly and experienced hyperprolactinemia. They were randomly assigned to the treatment group (aripiprazole adjunctive treatment) (n=30) or control group (non-adjunctive treatment) (n=30). The dosage of risperidone and paliperidone were maintained; and aripiprazole was maintained at 5mg/day during the 8-week study period...
March 30, 2016: Psychiatry Research
Martina Meduri, Giorgia Gregoraci, Valentina Baglivo, Matteo Balestrieri, Miriam Isola, Paolo Brambilla
BACKGROUND: Aripiprazole (ARP) has been shown to be effective in the treatment of bipolar disorder (BD). However, no prior investigation considered both randomized clinical trials (RCTs) and non-RCTs. We here evaluated the efficacy and safety of ARP compared with placebo (PCB) and other drugs at 3- and 12-weeks in adult and pediatric population including, for the first time, both observational and controlled studies. METHODS: All studies were systematically located by searching electronic sources (EMBASE, MEDLINE, CINHAIL, PsychINFO, Cochrane Central Register of Controlled Trials, Scopus and ClinicalTrials...
February 2016: Journal of Affective Disorders
Lisa Burback
UNLABELLED: A previously healthy 32-year-old woman developed cyclical mood swings after being prescribed cabergoline for a pituitary microprolactinoma. These mood swings persisted for over 2 years, at which point she developed an acute manic episode with psychotic features and was admitted to a psychiatry unit. Cabergoline was discontinued and replaced with aripiprazole 10 mg/day. Her manic episode quickly resolved, and she was discharged within 6 days of admission. The aripiprazole suppressed her prolactin levels for over 18 months of follow-up, even after the dose was lowered to 2 mg/day...
2015: Endocrinology, Diabetes & Metabolism Case Reports
Jingyuan Zhao, Xueqin Song, Xiaoqing Ai, Xiaojing Gu, Guangbiao Huang, Xue Li, Lijuan Pang, Minli Ding, Shuang Ding, Luxian Lv
OBJECTIVE: The present study aimed to evaluate the efficacy and safety of adjunctive aripiprazole treatment in schizophrenia patients with risperidone-induced hyperprolactinemia. METHODS: One hundred and thirteen patients who were receiving a stable dose of risperidone were randomly assigned to either adjunctive aripiprazole treatment (10 mg/day) (aripiprazole group) or no additional treatment (control group) at a 1:1 ratio for 8 weeks. Schizophrenia symptoms were measured using the Positive and Negative Syndrome Scale (PANSS)...
2015: PloS One
Jing-Xu Chen, Yun-Ai Su, Qing-Tao Bian, Li-He Wei, Rong-Zhen Zhang, Yan-Hong Liu, Christoph Correll, Jair C Soares, Fu-De Yang, Shao-Li Wang, Xiang-Yang Zhang
Hyperprolactinemia is an unwanted adverse effect associated with several antipsychotics. The addition of partial dopamine receptor agonist aripiprazole may attenuate antipsychotic-induced hyperprolactinemia effectively. However, the ideal dosing regimen for this purpose is unknown. We aimed to evaluate the dose effects of adjunctive treatment with aripiprazole on prolactin levels and hyperprolactinemia in schizophrenia patients. Stable subjects 18-45 years old with schizophrenia and hyperprolactinemia (i.e...
August 2015: Psychoneuroendocrinology
Isabella Pacchiarotti, Andrea Murru, Georgios D Kotzalidis, C Mar Bonnin, Lorenzo Mazzarini, Francesc Colom, Eduard Vieta
Drug-induced changes in serum prolactin (sPrl) levels constitute a relevant issue due to the potentially severe consequences on physical health of psychiatric patients such as sexual dysfunctions, osteoporosis and Prl-sensitive tumors. Several drugs have been associated to sPrl changes. Only antipsychotics have been extensively studied as sPrl-elevating agents in schizophrenia, but the extent to which bipolar disorder (BD) treatments affect sPrl levels is much less known. The objective of this systematic review is to summarize the evidence of the effects of drugs used in BD on Prl...
August 2015: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
Meiling Meng, Wei Li, Shaowei Zhang, Hongyan Wang, Jianhua Sheng, Jijun Wang, Chunbo Li
BACKGROUND: Hyperprolactinemia (HPL) is a common side effect of antipsychotic medications. Recent reports suggest that aripiprazole can ameliorate antipsychotic-induced HPL, but results are inconsistent and the single available systematic review only considered five studies. AIM: Conduct an updated meta-analysis of all randomized controlled trials (RCTs) about the efficacy and safety of aripiprazole as an adjunctive treatment for antipsychotic-induced hyperprolactinemia...
February 25, 2015: Shanghai Archives of Psychiatry
Fatemeh Ranjbar, Homayoun Sadeghi-Bazargani, Parisa Niari Khams, Asghar Arfaie, Azim Salari, Mostafa Farahbakhsh
BACKGROUND: Antipsychotics have been used for more than 50 years in the treatment of schizophrenia and many other psychiatric disorders. Prolactin levels usually increase in patients treated with risperidone. Aripiprazole, which has a unique effect as an antipsychotic, is a D2 receptor partial agonist. It is an atypical antipsychotic with limited extrapyramidal symptoms. Since it acts as an antagonist in hyperdopaminergic conditions and as an agonist in hypodopaminergic conditions, it does not have adverse effects on serum prolactin levels...
2015: Neuropsychiatric Disease and Treatment
Taro Kishi, Yuki Matsuda, Shinji Matsunaga, Nakao Iwata
BACKGROUND: We conducted a systematic review and meta-analysis of randomized controlled trials comparing aripiprazole with pooled antipsychotics in Japanese patients with schizophrenia. METHODS: We performed a literature search of data published in PubMed(®), the Cochrane Library database, the Japan Medical Abstracts Society, and PsycINFO(®) up to January 5, 2014. The odds ratio (OR), number-needed-to-harm (NNH), and standardized mean difference (SMD) based on a random effects model were calculated...
2015: Neuropsychiatric Disease and Treatment
Marek Kucka, Melanija Tomić, Ivana Bjelobaba, Stanko S Stojilkovic, Dejan B Budimirovic
Hyperprolactinemia is a common adverse in vivo effect of antipsychotic medications that are used in the treatment of patients with schizophrenia. Here, we compared the effects of two atypical antipsychotics, paliperidone and aripiprazole, on cAMP/calcium signaling and prolactin release in female rat pituitary lactotrophs in vitro. Dopamine inhibited spontaneous cAMP/calcium signaling and prolactin release. In the presence of dopamine, paliperidone rescued cAMP/calcium signaling and prolactin release in a concentration-dependent manner, whereas aripiprazole was only partially effective...
2015: Scientific Reports
Eiji Kirino
Bipolar disorder is a pernicious illness. Compared with the later-onset form, early onset bipolar disorder is associated with worse psychosocial outcomes, and is characterized by rapid cycling and increased risks of substance abuse and suicide attempts. Controlling mood episodes and preventing relapse in this group of pediatric patients requires careful treatment. Here, we review the effectiveness of aripiprazole for bipolar disorder in children and adolescents, with discussion of this drug's unique pharmacological profile and various clinical study outcomes...
2014: Adolescent Health, Medicine and Therapeutics
Thomas J Moore, Joseph Glenmullen, Donald R Mattison
IMPORTANCE: Severe impulse control disorders involving pathological gambling, hypersexuality, and compulsive shopping have been reported in association with the use of dopamine receptor agonist drugs in case series and retrospective patient surveys. These agents are used to treat Parkinson disease, restless leg syndrome, and hyperprolactinemia. OBJECTIVES: To analyze serious adverse drug event reports about these impulse control disorders received by the US Food and Drug Administration (FDA) and to assess the relationship of these case reports with the 6 FDA-approved dopamine receptor agonist drugs...
December 2014: JAMA Internal Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"